Startup
Neuropyscad
Sede: Praça Conde Agrolongo, N.º 123, 4700-314 Braga
Saúde , Tecnologia ,
The diagnosis of neuropsychiatric disorders still relies mostly on clinicians’ subjective impression of the patients’ clinical history, human eye-inspection of brain scans and memory.
Neuropsychiatric disorders such as Alzheimer’s and Parkinson’s are particularly difficult to diagnose, especially in its early stages, as symptoms are mild, unspecific and brain changes still subtle. In fact, at the time of the first appointment, 30% of Alzheimer’s and about 10% of Parkinson’s patients are misdiagnosed.
An incorrect or delayed diagnosis entails late and potentially harmful treatments and unnecessary costs.
By applying Artificial Intelligence to brain scan data (magnetic resonance imaging or nuclear medicine imaging), NeuroPsyCAD is able to recognize disease ‘signatures’ in a new patient’s brain scan.
We provide, in hours, a report containing a probability score per disease, to neurologists, psychiatrists and radiologists.
With NeuroPsyCAD’s report, diagnosis can achieve 54% more accuracy and be 5 times less costly in comparison to current clinical practice.